Abiraterone acetate is indicated in combination with methylprednisolone for the treatment of metastatic castration-resistant prostate cancer (CRPC)3 or with prednisone for the treatment of metastatic CRPC or metastatic high-risk castration-sensitive prostate cancer (CSPC)
Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 in a selective and irreversible manner via covalent binding mechanism. CYP17A1 is an enzyme that catalyzes the biosynthesis of androgen and is highly expressed in testicular, adrenal, and prostatic tumor tissue. More specifically, abiraterone inhibits the conversion of 17-hydroxyprognenolone to dehydroepiandrosterone (DHEA) by the enzyme CYP17A1 to decrease serum levels of testosterone and other androgens.
Abiraterone itself is poorly absorbed and is susceptible to hydrolysis by esterases. The salt form, abiraterone acetate, is a prodrug which has a much higher oral bioavailability and is also esterase resistant. Peak drug concentrations of abiraterone were reached in 1.5 – 4 hours. Abiraterone acetate was rapidly and completely deacetylated into abiraterone-the parent salt form was not detectable in early pharmacokinetic studies. Food and high fat meals increases absorption 4.4-fold.
Vdss= 19,669 ± 13,358 L
Abiraterone acetate is hydrolyzed into active metabolite abiraterone via esterases. CYP3A4 and SULT2A1 further metabolizes abiraterone into two inactive metabolites called abiraterone sulfate and N-oxide abiraterone sulfate.
Leading with integrity, delivering with impact — healthcare that moves lives forward.
SCO 215, 1st & 2nd Floor, Motor Market
Manimajra, Chandigarh, 160101
+91.172.4007092
md@barterandmarcinpharma.com
Copyright © Barter & Marcin Pharma. All Rights Reserved
